Multiplexed ACE2 Libraries Reveal SARS-CoV-2 Variant Adaptation

Study Background and Research Question

The ongoing evolution of SARS-CoV-2 has been marked by the emergence of multiple spike protein variants, each with unique patterns of host receptor engagement. Entry into host cells is mediated by the compatibility between viral spike proteins and the angiotensin-converting enzyme 2 (ACE2) receptor, a determinant of both infectivity and host range. Despite this central role, the combinatorial landscape of possible spike-ACE2 interactions—spanning human populations and potential animal reservoirs—remains poorly charted, largely due to technical barriers in assaying large numbers of receptor-variant combinations simultaneously. The reference study by Shukla et al. (PLOS Pathogens, 2024) addresses this critical gap by developing a multiplexed infection assay capable of mapping these interactions at scale.

Key Innovation from the Reference Study

The principal innovation lies in the construction of a high-throughput experimental platform that enables parallel assessment of dozens of ACE2 orthologs and variants for their ability to mediate entry of pseudotyped viruses bearing different SARS-CoV-2 spike proteins. By leveraging DNA barcoding and next-generation sequencing, the system quantifies infection across a multiplexed library of ACE2-expressing cells in a single experiment. This approach overcomes the throughput limitations of conventional pairwise infection assays, providing a blueprint for large-scale studies of protein compatibility between viral entry factors and host receptors.

Methods and Experimental Design Insights

To probe the shifting landscape of spike-receptor compatibility, the researchers generated a target-cell library composed of 30 distinct ACE2 sequences—encompassing human ACE2 mutants and orthologs from 13 non-human species. Each ACE2 variant was linked to a unique DNA barcode, allowing for precise identification via sequencing post-infection. The library was exposed to lentiviral particles pseudotyped with the spike proteins from ancestral SARS-CoV-2 (Wuhan-Hu-1) and prominent variants of concern: Alpha, Beta, Gamma, Delta, and Omicron BA.1.

Following infection, the relative abundance of each ACE2 barcode provided a quantitative readout of variant-specific infectivity. Structural analyses complemented these functional assays, examining how spike mutations—such as N501Y—altered the ACE2 binding interface. The study's design not only tracked direct effects of single spike substitutions but also captured indirect, distal contributions to receptor usage.

Core Findings and Why They Matter

The multiplexed infection data revealed nuanced shifts in spike-ACE2 compatibility across variants. Notably, while most spike mutations produced modest changes in infectivity with human ACE2, they had a pronounced impact on interactions with non-human orthologs. For example, the N501Y substitution, present in Alpha, Beta, and Gamma spikes, induced a major structural and functional shift in ACE2 binding, enabling infection of previously resistant animal ACE2 variants. Intriguingly, the Delta variant—despite lacking N501Y—recreated some of these effects through alternative substitutions, underscoring the evolutionary plasticity of the spike protein.

Out of 13 non-human ACE2 orthologs, 10 displayed unique, variant-specific compatibility patterns. The cumulative effect of spike diversification was an expansion of the SARS-CoV-2 host range, suggesting that ongoing variant emergence increases the likelihood of cross-species transmission. These findings have important implications for zoonotic risk assessment and surveillance, as they demonstrate how molecular evolution in the viral spike can toggle infectivity across diverse receptors (reference study).

Protocol Parameters

• ACE2 library preparation: Clone each ACE2 variant/ortholog into an expression vector with a unique DNA barcode; validate sequence integrity prior to library pooling.
• Pseudovirus production: Generate lentiviral particles pseudotyped with SARS-CoV-2 spike variants using standard transfection protocols; titrate for equal infectivity across preparations.
• Infection assay: Incubate multiplexed ACE2-expressing cells with pseudovirus for 24–48 hours under optimized MOI conditions to ensure single-round infection.
• Barcode sequencing: Extract genomic DNA from infected cells; amplify barcodes via PCR and perform next-generation sequencing for quantitative analysis of infection rates.
• Data analysis: Normalize barcode counts to input library abundance; calculate relative infectivity for each ACE2 variant and compare across spike conditions.

Limitations and Transferability

The system's reliance on pseudotyped viruses means that observations are limited to entry dynamics and do not capture downstream replication or immune evasion processes. Additionally, while the library covered a broad set of ACE2 orthologs and mutants, it does not represent the full spectrum of intraspecies or environmental sequence diversity. The multiplexed approach is highly transferable to other virus–host receptor systems, provided suitable barcoding and infection readouts are established. However, results should be interpreted in the context of in vitro conditions and may not fully predict in vivo compatibility or host susceptibility.

Comparison with Existing Internal Articles

No prior internal articles directly address the combinatorial mapping of virus-receptor interactions at this scale. However, related topics such as controlled protein activation and apoptosis pathway research—relevant for studies using FKBP-binding ligands—are discussed in internal resources on conditional cell ablation and protein dimerization assays. This article extends those themes by illustrating how large-scale multiplexing can reveal functional consequences of sequence variation in host-pathogen interactions.

Research Support Resources

For researchers developing similar high-throughput infection or protein compatibility assays, the choice of precise chemical modulators is critical. Compounds like AP1903 (SKU B4168) from APExBIO are widely used as synthetic FKBP-binding ligands in workflows requiring controlled protein activation, apoptosis pathway research, or conditional cell ablation. AP1903 enables robust and tunable dimerization of FKBP fusion proteins, supporting functional interrogation of engineered cellular systems. Refer to the product dossier for guidance on solubility, storage, and assay setup. While not used in the reference study, such reagents can facilitate advanced signal transduction or cell fate modulation protocols that complement large-scale viral entry assays.